Author of the publication

Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?

, , , and . Trends in immunology, 31 (1): 32--38 (January 2010)
DOI: 10.1016/j.it.2009.09.005

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles., , , , , , , , and . 35 (11): 3688--3696 (April 2014)Complement and coagulation: strangers or partners in crime?, , , , and . Trends in immunology, 28 (4): 184--192 (April 2007)Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?, , , , , , , , , and 6 other author(s). Stem cells (Dayton, Ohio), 32 (9): 2430--2442 (September 2014)Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses, , , , , , , , , and 3 other author(s). Plos One, 6 (7): -- (2011)Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition?, , , and . Trends in immunology, 31 (1): 32--38 (January 2010)Acute antibody-mediated complement activation mediates lysis of pancreatic islets cells and may cause tissue loss in clinical islet transplantation., , , , and . Transplantation, 85 (8): 1193--1199 (April 2008)Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface., , , and . Biomaterials, 26 (13): 1477--1485 (May 2005)Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation., , , , , , , , , and 4 other author(s). Xenotransplantation, 15 (4): 225--234 (June 2008)Complement C5a Functions as a Master Switch for the pH Balance in Neutrophils Exerting Fundamental Immunometabolic Effects., , , , , , , , , and 7 other author(s). Journal of immunology (Baltimore, Md. : 1950), 198 (12): 4846--4854 (June 2017)Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention, , , , , , , , , and 1 other author(s). European Journal of Clinical Investigation, 45 (4): 423--440 (March 2015)